Cantor Fitzgerald restated their hold rating on shares of Teladoc Health (NYSE:TDOC) in a research note published on Monday. They currently have a $83.00 target price on the health services provider’s stock.

“We characterize our estimates in our long-term DCF model as aggressive. We continue to believe the current share valuation already reflects the long-term growth opportunity. $83 DCF price target is based on continued high rates of revenue growth, improving operating margins, positive free cash flow beginning in 2018 and a 8.5% discount rate assumption. The Disclosure Section may be found on pages 3 – 4.Valuation Our DCF-based price target for TDOC shares is $83 in 12 months.”,” Cantor Fitzgerald’s analyst wrote.

Several other analysts also recently issued reports on the stock. KeyCorp upped their price target on shares of Teladoc Health from $90.00 to $94.00 and gave the company an overweight rating in a report on Friday, September 28th. TheStreet downgraded shares of Teladoc Health from a c rating to a d+ rating in a report on Tuesday, October 9th. Canaccord Genuity upped their price target on shares of Teladoc Health from $86.00 to $94.00 and gave the company a buy rating in a report on Friday, September 28th. Citigroup reaffirmed a buy rating and issued a $95.00 price target on shares of Teladoc Health in a report on Friday, September 28th. Finally, Jefferies Financial Group set a $95.00 price target on shares of Teladoc Health and gave the company a buy rating in a report on Friday, November 2nd. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teladoc Health currently has a consensus rating of Buy and an average price target of $83.42.

TDOC stock opened at $55.55 on Monday. Teladoc Health has a 52 week low of $30.88 and a 52 week high of $89.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Thursday, November 1st. The health services provider reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. The firm had revenue of $111.00 million for the quarter, compared to the consensus estimate of $109.94 million. Teladoc Health had a negative net margin of 31.32% and a negative return on equity of 14.05%. The firm’s revenue was up 61.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.55) earnings per share. On average, analysts expect that Teladoc Health will post -1.48 earnings per share for the current fiscal year.

In related news, insider Adam C. Vandervoort sold 5,549 shares of the company’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $67.18, for a total transaction of $372,781.82. Following the completion of the transaction, the insider now owns 2,934 shares of the company’s stock, valued at $197,106.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jason N. Gorevic sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 17th. The stock was sold at an average price of $70.29, for a total transaction of $1,757,250.00. Following the transaction, the chief executive officer now directly owns 511,184 shares of the company’s stock, valued at approximately $35,931,123.36. The disclosure for this sale can be found here. Insiders have sold 209,968 shares of company stock worth $12,958,568 in the last three months. Insiders own 3.95% of the company’s stock.

A number of hedge funds have recently modified their holdings of TDOC. Vanguard Group Inc. increased its position in shares of Teladoc Health by 26.9% in the third quarter. Vanguard Group Inc. now owns 5,874,182 shares of the health services provider’s stock worth $507,236,000 after acquiring an additional 1,244,388 shares in the last quarter. Vanguard Group Inc grew its holdings in Teladoc Health by 26.9% during the 3rd quarter. Vanguard Group Inc now owns 5,874,182 shares of the health services provider’s stock valued at $507,236,000 after purchasing an additional 1,244,388 shares in the last quarter. Bank of America Corp DE grew its holdings in Teladoc Health by 82.8% during the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after purchasing an additional 853,076 shares in the last quarter. Capital International Investors acquired a new stake in Teladoc Health during the 3rd quarter valued at $71,239,000. Finally, Macquarie Group Ltd. grew its holdings in Teladoc Health by 464.0% during the 3rd quarter. Macquarie Group Ltd. now owns 558,436 shares of the health services provider’s stock valued at $48,221,000 after purchasing an additional 459,422 shares in the last quarter.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: What are CEFs?

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.